News Sentiment

CUE sentiment intelligence

Cue Biopharma news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 36.78 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+30.1% over one week, +49.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Form 4 Cue Biopharma For: 15 July By Investing.com

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction 30.1% Price confirming higher
Trend fit Trend active 49.9% over four weeks
Fair value -4.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 46
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 19
TradingView 10
GlobeNewswire 7
Market source 6
Investing.com 3
Moomoo 3
Investing.com Canada 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 47
Earnings 13
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
AD HOC NEWS Direct company coverage

Cue Biopharma Inc outlines its immunotherapy approach for long-term investors

Cue Biopharma Inc is a biotechnology company focused on developing targeted biologic therapies to modulate the human immune system for cancer and autoimmune diseases. Its business model centers on creating engineered biologic molecules that selectively engage disease-specific T c

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 15:39
Source
AD HOC NEWS
Stock Titan Direct company coverage

Cue Biopharma, Inc. SEC Filing

This article announces an EFFECT filing by Cue Biopharma, Inc. (CUE) with the SEC, indicating the effectiveness of its S-3 registration statement. The effectiveness date is July 1, 2026, at 4:00 P.M. The filing is deemed neutral in both impact and sentiment by Rhea-AI.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 10:09
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Cue Biopharma, Inc. – LS:A426PN

This page provides financial information for Cue Biopharma, Inc. (A426PN) traded on the Lang & Schwarz Tradecenter, specifically focusing on its "Price to book forward" metric. The article indicates that market data is provided by ICE Data Services, reference data by FactSet, and

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cue Biopharma, Inc. – NASDAQ:CUE

This page provides financial data, specifically the price to book forward ratio, for Cue Biopharma, Inc. (NASDAQ: CUE). It also lists various tools and services offered by TradingView, including market data, charting libraries, and community features. The article indicates that t

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cue Biopharma, Inc. – LS:A426PN

This article focuses on the enterprise value to revenue forward a financial metric for Cue Biopharma, Inc. (A426PN). It indicates that the information is provided by TradingView, sourcing data from ICE Data Services, FactSet, American Bankers Association, and Quartr for SEC filin

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Cue Biopharma, Inc. – LS:A426PN

This article provides the enterprise value to EBITDA forward for Cue Biopharma, Inc. under the ticker LS:A426PN. The data is presented within a financial market context, likely TradingView, where users can find financial information, news, and community discussions. It serves as

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cue Biopharma, Inc. – LS:A426PN

This article provides financial information for Cue Biopharma, Inc. (LS:A426PN), specifically focusing on its forward price-to-earnings ratio. The content appears on TradingView, listing key financial metrics and indicating that the market for this stock is closed with no recent

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 21:11
Source
TradingView